Compare C3.ai Inc (AI) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Hims and Hers Health Inc — how do they compare? C3.ai Inc trades at $10.28 (market cap $1.65B), while Hims and Hers Health Inc trades at $29.76 (market cap $7.12B). The key difference: Hims and Hers Health Inc is far larger — about 4.3× C3.ai Inc's market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, C3.ai Inc nearer its low. Which is the better fit depends on your goals.
| AI | HIMS | |
|---|---|---|
Market Cap | $1.65B | $7.12B |
Sector | Technology | Health |
52-Week High | $19.66 | $62.76 |
52-Week Low | $7.76 | $14.52 |
Enterprise Value | $1.08B | $7.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.40, up 1.76% with a bullish technical signal despite negative profitability metrics. The company reported Q1 2026 earnings beat but maintains negative net margins of -187.95%. Recent news highlights C3.ai being named a leader in AI platforms by Forrester Research, while technical indicators show RSI levels near 90 suggesting overbought conditions.
The stock faces significant fundamental challenges with persistent losses and negative cash flow, though revenue growth and leadership positioning in enterprise AI provide long-term potential. Analyst consensus is mixed with a $10.20 price target, indicating cautious optimism amid execution risks and competitive pressures in the AI software market.
HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.
The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
